Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
29 082 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32022R0692

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32022R0692

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X&xxxx;XXXXXXXXX XXXXXXXXX (XX) 2022/692

xx xxx 16. února 2022,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxx xxxx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (ES) x.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx

(Xxxx x&xxxx;xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x&xxxx;xxxxxxx na Xxxxxxx x&xxxx;xxxxxxxxx Evropské xxxx,

x&xxxx;xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (ES) x.&xxxx;1272/2008 xx xxx 16.&xxxx;xxxxxxxx&xxxx;2008 o klasifikaci, xxxxxxxxxx x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx, x&xxxx;xxxxx a zrušení xxxxxxx 67/548/XXX x&xxxx;1999/45/XX a o změně xxxxxxxx (XX) x.&xxxx;1907/2006&xxxx;(1), x&xxxx;xxxxxxx xx xx.&xxxx;37 xxxx.&xxxx;5 xxxxxxxxx nařízení,

vzhledem x&xxxx;xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x&xxxx;xxxxx 3 přílohy XX xxxxxxxx (XX) x.&xxxx;1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikací x&xxxx;xxxxxxxx xxxxxxxxxxxx látek na xxxxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxx 2 až 5 xxxxxxx X&xxxx;xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře pro xxxxxxxx látky (xxxx xxx „agentura“) xxxx x&xxxx;xxxxxxx s článkem 37 nařízení (XX) č. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx xxxxx a na xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx jiných látek. Xxxx, xx Xxxxx xxx xxxxxxxxxx xxxxx (XXX) agentury xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxx, xxxxxx x&xxxx;xxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx&xxxx;(2):

—

xxxxxxxxxx xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019 pro xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, produkty xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx amorfní xxxx xxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxx (XXX), [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 4. května 2020 xxx β-cyfluthrin (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx- (1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 4. května 2020 xxx xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-kyan-N 1-xxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxx,

—

xxxxxxxxxx xx xxx 11. června 2020 xxx xxxx telluričitý,

—

stanovisko xx xxx 11. června 2020 xxx tribromderivát 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxxxx (XXX); 5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxol,

—

stanovisko ze xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxx,

—

xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxx (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxxx kyselinu,

—

stanovisko ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx fluopikolid (ISO); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 11. června 2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx xxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctové xxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxxxx xxxx na xxxxxx Xxxxxxxx xxxxxx,

—

xxxxxxxxxx xx xxx 17. září 2020 xxx xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx),

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxx xxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx dne 17. září 2020 xxx chinoklamin (ISO); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx 4,4’-xxxxx(xxxxxxxxxxxxxxxxxxxxx),

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxx-4-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 17. září 2020 pro xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx,

—

xxxxxxxxxx xx xxx 17. září 2020 xxx 1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX],

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX],

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxx xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxx,

—

xxxxxxxxxx ze dne 17.&xxxx;xxxx&xxxx;2020 xxx 2-ethyl-2-{[(1-oxoallyl)oxy]methyl}propan-1,3-diyl-diakrylát; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx s aerodynamickým xxxxxxxx xxxxxx xxx 50 μx],

—

xxxxxxxxxx xx xxx 17. září 2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující ≥ 0,1 % xxxx. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším než 50 μx],

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 pro xxxxxx xxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx 2,4,6-xxx-xxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx pyridalyl (XXX); 2,6-dichlor-4-(3,3-dichlorallyloxy)fenyl{3-[5-(trifluormethyl)-2-pyridyloxy]propyl}ether,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxx-2-xxxxx-1-xxxx, xxxxxx xxx; xxxxxx xxx pyrithionu; xxxxxxxxx sodný,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. října 2020 xxx 2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. října 2020 xxx 4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx A,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx,

—

xxxxxxxxxx xx dne 8.&xxxx;xxxxx&xxxx;2020 xxx dimoxystrobin (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxx 4,4’-xxxxxxxxxxxxxxx; bisfenol X,

—

xxxxxxxxxx ze dne 10.&xxxx;xxxxxxxx&xxxx;2020 pro 2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Disperse Blue 124,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro xxxxxxxx xxxxxxxxxxxxxxxxxx; xxxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxx methyl-N-(isopropoxykarbonyl)-L-valyl-(3RS)-3-(4-chlorfenyl)-β-alaninát; xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx xxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[xxxxx-(X10-X13, rozvětvené, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou xxxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 1,3,5-triazin-2,4,6-triamin; xxxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxx reakční xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [xxxxxxxxx xxxxx ≥ 78 % syn-isomerů x&xxxx;≤&xxxx;15&xxxx;% anti-isomerů], xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxxxxxx margosy, xxxxxxxx [x&xxxx;xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx, xxxxxxxxxxx xxxxx x&xxxx;xxxx xxxxxxxxxx organickými xxxxxxxxxxxx],

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro xxxx xxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxxx (XXX), 3-isopropyl-2,1,3-benzothiadiazin-4-on-2,2-dioxid,

—

stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx posouzení xxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxx xxxxxxxx 2-butoxyethan-1-olu; ethylenglykol-monobutyl-etheru (XXXX) xx žádost Xxxxxxxx komise.

(3)

Byly xxxxxxxx xxxxxxxxx informace, které xxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx xx xxxxxxxxxxxx XXX ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli; xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx opětovného xxxxxxxxx xxxxxxxx toxicity {[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx x&xxxx;xxxxxx pentasodných x&xxxx;xxxxxxxxxxxxxxx solí na xxxxxx Xxxxxxxx komise, xx dne 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxx amonný, xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxx xxxxxxxxx, xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx posouzení xxxxxx informací x&xxxx;xxxxxx xxxxxxxxx toxicitě 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (EGBE) na xxxxxx Evropské komise x&xxxx;xx dne 10. prosince 2020 xxx xxxxxxx.

(4)

Xxxxxx tyto xxxxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx xx za xxxxxxxxxx x&xxxx;xxxx, aby xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxxx XXX. Xx xxxxxxx xxxxxxxxx xxxxxxxxxxx v uvedených xxxxxxxxxxxx xx proto xxxxxx zavést, xxxxxxxxxxxx xxxx zrušit xxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx dotčených xxxxx.

(5)

Xxxx, xx xxxx Xxxxxx předáno stanovisko XXX, byly xxxxxxxx xxxxxxxxx informace xxxxxxxx xx xxxxxx inhalační xxxxxxxx xxxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx. Xxxxxxxxxxx xxxxxxxxxx, 1,1,1-trimethyl-N-(trimethylsilyl)-, xxxxxxxx xxxxxxxxx s oxidem xxxxxxxxxx; xxxxxxxxxxx syntetického xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx xxxx akutní xxxxxxxxx xxxxxxxx kategorie 2, xxxxxxxxxx ve xxxxxxxxxx XXX xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019, xx neměla xxx zařazena xx xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008, neboť Xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx a neshledala, xx xx bylo xxxxx xxxxx posouzení XXX. Do xxxxxxx XX nařízení (ES) x.&xxxx;1272/2008 by však xxxx být xxxxxxxx xxxxxxxxxxx xxxx látky xxxx STOT RE 2, doporučená xx xxxxxxxxxx xxxxxx XXX xx xxx 5. prosince 2019, xxxxx xxxxxx xxxxxxxx xxxxx xxxx informace, xxxxx by xxxxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxxxx.

(6)

Xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxxx xxxx xxx odpovídajícím xxxxxxxx xxxxxxx.

(7)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx harmonizovaných xxxxxxxxxxx xx xxxxxx xxx xxxxxxxxxx ihned, jelikož xxxxxxxxxx potřebují určitou xxxx na to, xxx xxxxxxxxxxxx xxxxxxxxxx x&xxxx;xxxxxx látek x&xxxx;xxxxx xxxxx nebo xxxxxxxxxxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxx xxxxxxxxx xxxxxx, na xxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxxx. Xxxx xxxx xx xxxxxx xxxxxxxx x&xxxx;xxxx, xxx xxxxxxxxxx měli dostatek xxxx přijmout xxxxxxxx xxxxx x&xxxx;xxxxxxxxx trvalého xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx vznikají x&xxxx;xxxxxxxx xxxx provedených xxxxx xxxxxx xxxxxxxx. Xxxxxxxxxxx xx xxxx xxxx xxx xxxxxxxx xxxxxxxx xxxx nebo xxxxxxxxxxxxx xxxxxxxxxxxxx klasifikace x&xxxx;xxxxxxxxxxxxx způsobem xxxxxxxxxxx xxxxxxxxxx x&xxxx;xxxxxx xx xxxxxxxxxxx xxxxxxx xxxx xxxxx použitelnosti tohoto xxxxxxxx, aby xxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxx xxxxxxxx xxxxxx x&xxxx;xxxxxxxxx xxxxxxxxx x&xxxx;xxx xx dodavatelům xxxxxxxx xxxxxxxxxx xxxxxxxx,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx&xxxx;1

Xxxxx xxxxxxxx (XX) x.&xxxx;1272/2008

Xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 se xxxx v souladu s přílohou xxxxxx xxxxxxxx.

Článek 2

Vstup x&xxxx;xxxxxxxx a použitelnost

Toto xxxxxxxx xxxxxxxx v platnost xxxxxxxx dnem xx xxxxxxxxx x&xxxx;Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx se xxx dne 23. listopadu 2023.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx tohoto xxxxxx xxxxx xxx látky x&xxxx;xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxx xxxxxxxxx xxx xxx xxxx vstupu x&xxxx;xxxxxxxx.

Xxxx nařízení xx xxxxxxx x&xxxx;xxxxx rozsahu x&xxxx;xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.

V Bruselu xxx 16. února 2022.

Xx Xxxxxx

xxxxxxxxxxx

Xxxxxx XXX XXX XXXXX

(1)&xxxx;&xxxx;Xx. věst. X&xxxx;353, 31.12.2008, s. 1.

(2)  Stanoviska xxxx xxxxxxxx xx xxxx xxxxxxxxxxx stránce: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/. – Xxxxxxxxxx xx xxx 11. června 2020 x&xxxx;xx xxx 10. prosince 2020 xxxxxxxx xx xxxxxxxxxx xxxxxxxxx xx xxxxxx Xxxxxxxx xxxxxx xxxx x&xxxx;xxxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxx-xx/xxx-xx-xxx/xxxxxxxxx-xxx-xxxx-xxxxxxxxxx/xxxxxxxx-xx-xxx-xxx-xxxxxxx-xxxxx-xxxxxxxx-xxxx-x-xxxxxxxxx-xxxxxxxx-xxxxxxxx

PŘÍLOHA

Příloha XX xxxxxxxx (XX) x.&xxxx;1272/2008 se xxxx xxxxx:

1)

x&xxxx;xxxxx 3 xx xxxxxxx 3 xxxx takto:

a)

vkládají se xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x&xxxx;XXX

Xxxxxxxx

Xxxx xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a signálních xxxx

Xxxx xxxxxxxxxxxx vět o nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

„014-052-00-7

xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxxx v nanoformě x&xxxx;xxxxxxxxxx úpravou

272-697-1

68909-20-6

STOT XX 2

X373 (xxxxx) (xxxxxxxxxx)

XXX08

Xxx

X373 (xxxxx) (xxxxxxxxxx)

XXX066“

„035-005-00-7

xxxxxx xxxxxx

235-183-8

12124-97-9

Xxxx. 1X

Xxxx.

XXXX XX 3

XXXX XX 1

Xxx Xxxxx. 2

X360XX

X362

X336

X372 (xxxxxxx xxxxxx)

X319

XXX08

XXX07

Xxx

X360XX

X362

X336

X372 (xxxxxxx systém)

H319“

„050-032-00-4

dibutylcín-bis(2-ethylhexanoát)

220-481-2

2781-10-4

Muta. 2

Repr. 1X

XXXX XX 1

X341

X360XX

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (imunitní xxxxxx)“

„050-033-00-X

xxxxxxxxxx-xxxxxxxx

213-928-8

1067-33-0

Xxxx. 2

Repr. 1X

XXXX XX 1

H341

H360FD

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (imunitní xxxxxx)“

„052-001-00-0

xxxxxx

236-813-4

13494-80-9

Xxxx. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„052-002-00-6

xxxx telluričitý

231-193-1

7446-07-3

Repr. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„056-005-00-3

xxxxxxxxx xxxxxxx-xxxxxxxx

237-222-4

13701-59-2

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

X360XX

X332

X301

XXX08

XXX06

Xxx

X360XX

X332

X301

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (prach nebo xxxx)

xxxxxx:

XXX&xxxx;= 100&xxxx;xx/xx XX“

„601-097-00-8

xxxxxxxxxxxx

203-132-9

103-65-1

Xxxx. Xxx. 3

Xxx. Xxx. 1

XXXX XX 3

Xxxxxxx Xxxxxxx 2

X226

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X304

X335

X411“

„603-243-00-6

xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx

253-057-0

36483-57-5; 1522-92-5

Xxxx. 1B

Muta. 2

X350

X341

XXX08

Xxx

X350

X341“

„604-096-00-0

xxxxxxxxxxxxxxxx (ISO); 5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxol

200-076-7

51-03-6

STOT XX 3

Eye Irrit. 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H335

H319

H400

H410

GHS07

GHS09

Wng

H335

H319

H410

EUH066

M = 1

X&xxxx;= 1“

„604-097-00-6

2,4,6-xxx-xxxx-xxxxxxxxxx

211-989-5

732-26-3

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxxx Xxxx. 1X

X360X

X302

X373 (xxxxx)

X317

XXX08

XXX07

Xxx

X360X

X302

X373 (xxxxx)

X317

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx XX“

„604-098-00-1

4,4’-xxxxxxxxxxxxxxx; xxxxxxxx X

201-250-5

80-09-1

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„606-153-00-5

xxxxxxxxxx

204-337-6

119-61-9

Xxxx. 1X

X350

XXX08

Xxx

X350“

„606-154-00-0

xxxxxxxxxxx (ISO); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx

220-529-2

2797-51-5

Xxxx. 2

Xxxx. 2

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxxxx. 2

Skin Sens. 1&xxxx;X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H351

H361d

H302

H373 (krevní xxxx, xxxxxxx)

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X361x

X302

X373 (xxxxxx xxxx, xxxxxxx)

X319

X317

X410

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„607-756-00-6

xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx

227-561-6

5888-33-5

Xxxx Sens. 1&xxxx;X

X317

XXX07

Xxx

X317“

„607-757-00-1

xxxxxxxxx (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx

216-485-9

1596-84-5

Xxxx. 2

H351

GHS08

Wng

H351“

„607-758-00-7

4,4′-oxydi(benzensulfonohydrazid)

201-286-1

80-51-3

Self-react. X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H242

H400

H410

GHS02

GHS09

Dgr

H242

H410

M = 1

X&xxxx;= 1“

„607-759-00-2

xxxxxx-4-xxxxxxxxxxxxxxx

216-407-3

1576-35-8

Xxxx-xxxxx. X

X242

XXX02

Xxx

X242“

„607-760-00-8

2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Xxxx 124

239-203-6

15141-18-1

Xxxx Xxxx. 1&xxxx;X

X317

XXX07

Xxx

X317

Xxxx Xxxx. 1&xxxx;X; X317: C ≥ 0,001 %“

„607-761-00-3

perfluorheptanová xxxxxxxx; xxxxxxxxxxxxxxxxxxxxx xxxxxxxx

206-798-9

375-85-9

Xxxx. 1X

XXXX RE 1

X360X

X372 (xxxxx)

XXX08

Xxx

X360X

X372 (játra)“

„607-762-00-9

methyl-N-(isopropoxykarbonyl)-L-valyl-(3RS)-3-(4-chlorfenyl)-β-alaninát; xxxxxxxxxxx

-

283159-90-0

Xxxx. 2

Xxxxxxx Chronic 2

H351

H411

GHS08

GHS09

Wng

H351

H411“

„607-763-00-4

6-[alkyl-(C12-C18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx, xxxxx a tris(2-hydroxyethyl)amonné xxxx

-

-

Xxxx. 1X

Xxx Xxxxx. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319“

„607-764-00-X

6-[alkyl-(C10-C13, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx

-

2156592-54-8

Xxxx. 1X

Xxx Xxxxx. 2

X360XX

X319

XXX08

XXX07

Xxx

X360XX

X319“

„607-765-00-5

6-[xxxxx-(X12-X18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová xxxxxxxx

-

-

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„613-341-00-0

xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx

277-728-2

74115-24-5

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X&xxxx;= 1“

„613-342-00-6

xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx

200-385-7

58-55-9

Xxxx. 1X

X360X

XXX08

Xxx

X360X“

„613-343-00-1

xxxxxxxxx (XXX); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx

-

179101-81-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X&xxxx;= 1&xxxx;000

X&xxxx;= 100“

„613-344-00-7

xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx; sodná xxx xxxxxxxxxx; xxxxxxxxx xxxxx

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Xxxxx Xxx. 3

Acute Xxx. 3

Xxxxx Xxx. 4

XXXX RE 1

Skin Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 2

X331

X311

X302

X372 (nervový xxxxxx)

X315

X319

X317

X400

X411

XXX06

XXX08

XXX09

Xxx

X331

X311

X302

X372 (xxxxxxx xxxxxx)

X315

X319

X317

X410

XXX070

xxxxxxxxx:

XXX&xxxx;= 0,5&xxxx;xx/x (xxxxx nebo xxxx)

xxxxxxxx:

XXX&xxxx;= 790&xxxx;xx/xx TH

orální:

ATE = 500&xxxx;xx/xx XX

X&xxxx;= 100“

„613-345-00-2

1,3,5-triazin-2,4,6-triamin;

melamin

203-615-4

108-78-1

Carc. 2

XXXX XX 2

X351

X373 (xxxxxx xxxxx)

XXX08

Xxx

X351

X373 (xxxxxx xxxxx)“

„615-046-00-2

1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX]

220-474-4

2778-42-9

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317“

„615-047-00-8

1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX]

222-852-4

3634-83-1

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317

Xxxx Sens. 1&xxxx;X; X317: X&xxxx;≥&xxxx;0,001&xxxx;%“

„615-048-00-3

2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx

218-485-4

2162-73-4

Xxxx. Xxxx. 1

Xxxx Xxxx. 1

X334

X317

XXX08

Xxx

X334

X317“

„615-049-00-9

1,5-xxxxxxxxxxxxxxxxxxxx

[xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% hmot. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším xxx 50 μm]

221-641-4

3173-72-6

STOT XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Resp. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Chronic 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412“

„615-050-00-4

1,5-diisokyanatonaftalen

[obsahující &xx;&xxxx;0,1&xxxx;% xxxx. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μx]

221-641-4

3173-72-6

Xxxxx Xxx. 2

STOT XX 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

X330

X335

X315

X319

X334

X317

X412

XXX06

XXX08

Xxx

X330

X335

X315

X319

X334

X317

X412

xxxxxxxxx:

XXX&xxxx;= 0,27&xxxx;xx/x (xxxxx nebo mlha)“

„616-237-00-3

fluopikolid (XXX); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx

-

239110-15-7

Xxxx. 2

H361d

GHS08

Wng

H361d“

„616-238-00-9

triamid xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx

477-690-9

874819-71-3

Xxxx. 1B

STOT XX 2

H360Fd

H373 (xxxxxxx)

XXX08

Xxx

X360Xx

X373 (xxxxxxx)“

„616-239-00-4

X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx

-

1255734-28-1

Xxxx. 2

Acute Xxx. 4

Xxxx Sens. 1X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X317

X410

xxxxxxxxx:

XXX&xxxx;= 2,2&xxxx;xx/x (xxxxx nebo mlha)

M = 10

X&xxxx;= 1“

„616-240-00-X

reakční xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% anti-isomerů], xxxxxxxxxx

-

881685-58-1

Xxxx. 2

Xxxx. 1X

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X351

X360X

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X360X

X317

X410

Xxxx. 1X; X360X:

X&xxxx;≥&xxxx;3&xxxx;%

X&xxxx;= 10

X&xxxx;= 10“

„650-058-00-1

Xxxxxxx, xxxxxxx [x&xxxx;xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx, xxxxxxxxxxx xxxxx x&xxxx;xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx]

283-644-7

84696-25-3

Xxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 1

H361d

H317

H410

GHS08

GHS07

GHS09

Wng

H361d

H317

H410

M = 10“

x)

xxxxxxx xxxxxxxxxxxx indexovým xxxxxx 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 xx xxxxxxxxx těmito xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx a ATE

Poznámky

Kódy xxxx x&xxxx;xxxxxxxxx nebezpečnosti

Kódy xxxxxxxxxxxx vět o nebezpečnosti

Kódy xxxxxxxxxxx symbolů x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx vět x&xxxx;xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx o nebezpečnosti

„014-001-00-9

trichlorsilan

233-042-5

10025-78-2

Flam. Liq. 1

Xxxxx-xxxxx. 1

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1 A

Eye Dam. 1

X224

X260

X331

X302

X314

X318

XXX02

XXX06

XXX05

Xxx

X224

X260

X331

X302

X314

XXX014

XXX029

XXX071

xxxxxxxxx:

XXX&xxxx;= 7,6&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1&xxxx;000  mg/kg XX“

„023-001-00-8

xxxx xxxxxxxxx

215-239-8

1314-62-1

Xxxx. 2

Xxxx. 1X

Xxxx. 2

Xxxx.

Xxxxx Xxx. 3

Xxxxx Xxx. 2

STOT XX 3

XXXX XX 1

Aquatic Xxxxxxx 2

X341

X350

X361xx

X362

X301

X330

X335

X372 (xxxxxxx xxxxx, xxxxxxxxxx)

X411

XXX06

XXX08

XXX09

Xxx

X341

X350

X361xx

X362

X301

X330

X335

X372 (xxxxxxx xxxxx, vdechování)

H411

inhalační:

ATE = 0,05 mg/l (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 220&xxxx;xx/xx XX“

„601-024-00-X

xxxxx

202-704-5

98-82-8

Xxxx. Xxx. 3

Xxxx. 1X

Xxx. Tox. 1

XXXX XX 3

Xxxxxxx Xxxxxxx 2

X226

X350

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X350

X304

X335

X411“

„603-014-00-0

2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxx

203-905-0

111-76-2

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X331

X302

X315

X319

XXX06

Xxx

X331

X302

X315

X319

xxxxxxxxx:

XXX&xxxx;= 3&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1 200 &xxxx;xx/xx XX“

„603-107-00-6

2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-906-6

111-77-3

Xxxx. 1X

X360X

XXX08

Xxx

X360X

Xxxx. 1X; X360X: X&xxxx;≥&xxxx;3&xxxx;%“

„604-030-00-0

4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx X

201-245-8

80-05-7

Xxxx. 1X

XXXX XX 3

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X335

X318

X317

X400

X410

XXX08

XXX07

XXX05

XXX09

Xxx

X360X

X335

X318

X317

X410

X&xxxx;= 1

X&xxxx;= 10“

„607-111-00-9

2-ethyl-2-{[(1-oxoallyl)oxy]methyl}propan-1,3-diyl-diakrylát; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx;

xxxxxxxxxxxxxxxxx-xxxxxxxxxx

239-701-3

15625-89-5

Xxxx. 2

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X315

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X315

X319

X317

X410

X&xxxx;= 1

X&xxxx;= 1

X“

„607-230-00-6

2-xxxxxxxxxxxxx kyselina x&xxxx;xxxx xxxx, x&xxxx;xxxxxxxx xxxx, xxxxx xxxx xxxxxxx xxxxx x&xxxx;xxxx xxxxxxx

-

-

Xxxx. 1B

H360D

GHS08

Dgr

H360D“

„607-253-00-1

cyfluthrin (ISO); [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

269-855-7

68359-37-5

Xxxx.

Xxxxx Xxx. 2

Xxxxx Xxx. 2

STOT XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H362

H330

H300

H370 (nervový xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (nervový xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,14&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 14&xxxx;xx/xx TH

M = 1&xxxx;000&xxxx;000

X&xxxx;= 1&xxxx;000&xxxx;000 “

„607-254-00-7

β-xxxxxxxxxx (XXX); reakční xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx a rel-(R)-kyan(4-fluor-3-fenoxyfenyl)methyl-(1S,3R)-3-(2,2-dichlorethenyl)-2,2-dimethylcyklopropan-1-karboxylát

-

1820573-27-0

Lact.

Acute Xxx. 2

Xxxxx Tox. 2

STOT XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H362

H330

H300

H370 (xxxxxxx xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,081&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 11&xxxx;xx/xx XX

X&xxxx;= 1 000 000

M = 1 000 000 “

„607-734-00-6

xxxxxxxxxxx-2,2‘,2“,2“‘,2“&xxxx;“ -(ethan-1,2-diylnitrilo)pentaacetát

404-290-3

7216-95-7

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxxxx. 2

H360D

H332

H373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

X319

Xxxx. 1B; X360X: C ≥ 3 %

inhalační:

ATE = 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„607-735-00-1

{[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx

200-652-8

67-43-6

Xxxx. 1X

Xxxxx Tox. 4

XXXX RE 2

Xxx Xxxxx. 2

H360D

H332

H373 (vdechování)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (xxxxxxxxxx)

X319

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx mlha)“

„607-736-00-7

pentanatrium-[(karboxylatomethyl)iminobis(ethylennitrilo)tetraacetát]

205-391-3

140-01-2

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

X360X

X332

X373 (vdechování)

GHS08

GHS07

Dgr

H360D

H332

H373 (xxxxxxxxxx)

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„608-032-00-2

xxxxxxxxxxx (XXX); (1E)-N-[(6-chlorpyridin-3-yl)methyl]-N’-kyan-N-methylethanimidamid; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-xxxx-X 1-xxxxxxxxxxxxxxxx

-

135410-20-7&xxxx;160430-64-8

Xxxx. 2

Acute Xxx. 3

Xxxxxxx Xxxxxxx 1

Xxxxxxx Xxxxx 1

H361d

H301

H410

H400

GHS08

GHS06

GHS09

Dgr

H361d

H301

H410

orální:

ATE = 140&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„609-042-00-X

pendimethalin (XXX); N-(1-ethylpropyl)-2,6-dinitro-3,4-xyliden

254-938-2

40487-42-1

Repr. 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X400

X410

XXX08

XXX09

Xxx

X361x

X410

X&xxxx;= 100

X&xxxx;= 10“

„613-012-00-1

xxxxxxxx (XXX); 3-xxxxxxxxx-1X-2,1,3-xxxxxxxxxxxxxxx-4(3X)-xx-2,2-xxxxxx

246-585-8

25057-89-0

Xxxx. 2

Xxxxx Xxx. 4

Eye Xxxxx. 2

Xxxx Xxxx. 1

X361x

X302

X319

X317

XXX08

XXX07

Xxx

X361x

X302

X319

X317

xxxxxx: XXX&xxxx;= 1&xxxx;600 &xxxx;xx/xx XX“

„616-164-00-7

xxxxxxxxxxxxx (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx

149961-52-4

Xxxx. 2

Repr. 2

Xxxxx Xxx. 4

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H351

H361d

H332

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H332

H410

inhalační:

ATE = 1,3&xxxx;xx/x (prach xxxx xxxx)

X&xxxx;= 100

X&xxxx;= 100“

c)

položka xxxxxxxxxxxx indexovému xxxxx 615-007-00-X xx xxxxxxx.